332099-11-3

Usage

Uses

Used in Organic Synthesis:
2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid is used as a building block in organic synthesis for the creation of various pharmaceutical compounds. Its unique core structure and functional group enable the formation of diverse chemical entities with potential therapeutic applications.
Used in Medicinal Chemistry:
In medicinal chemistry, 2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid is employed as a key intermediate in the synthesis of bioactive molecules. Its presence in the molecular structure can impart specific pharmacological properties, making it a valuable component in the development of new drugs.
Used in Drug Development:
2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid is utilized in drug development as a precursor for the synthesis of potential therapeutic agents. Its incorporation into drug candidates can enhance their efficacy and selectivity, contributing to the advancement of novel treatments for various diseases.
Used in Antiviral Applications:
2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid has been studied for its potential antiviral properties. It is used as a starting material in the development of antiviral agents, with the aim of inhibiting viral replication and reducing the severity of viral infections.
Used in Anti-inflammatory Applications:
2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid has also been investigated for its anti-inflammatory potential. It is used in the research and development of anti-inflammatory drugs, which can help alleviate inflammation and associated symptoms in various conditions.
Used in Novel Material Development:
2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid has found applications in the development of novel materials, where its unique chemical properties can be harnessed to create innovative products with specific functionalities.
Used as a Reagent in Chemical Research:
In chemical research, 2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid is employed as a reagent to facilitate various chemical reactions and processes. Its presence can aid in the synthesis of complex molecules and the study of reaction mechanisms, contributing to the advancement of chemical knowledge and techniques.

Relevant academic research and scientific papers

The discovery of fused pyrrole carboxylic acids as novel, potent d-amino acid oxidase (DAO) inhibitors

The 'NMDA hypofunction hypothesis of schizophrenia' can be tested in a number of ways. DAO is the enzyme primarily responsible for the metabolism of d-serine, a co-agonist for the NMDA receptor. We identified novel DAO inhibitors, in particular, acid 1, which demonstrated moderate potency for DAO in vitro and ex vivo, and raised plasma d-serine levels after dosing ip to rats. In parallel, analogues were prepared to survey the SARs of 1.

FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE

This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O?X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.

Use of glycogen phosphorylase inhibitors

The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

This invention relates to compounds of Formula I or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compou